Neurology

In previously reported data, AOC 1020 demonstrated a consistent reduction in double homeobox 4 regulated…

The head of global clinical development for immunology/bone at talked about findings presented at CTAD…

Rapport Therapeutics’ is actively recruiting patients for its phase 2a trial investigating its lead therapy…

John Michael Schreiber, MD, provides an overview of genetic testing, detailing the different types, including…

The vice president of scientific engagement at Alzheimer's Association talked about the emergence of blood…

The cAPPricorn-1 Phase 2 trial will assess mivelsiran’s efficacy in CAA, focusing on reducing the…

Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved…

Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc…

The professor of psychiatry and pharmacology at the University of Toronto talked about results from…

Michael McDermott, MD, chief medical executive at Baptist Health Miami Neuroscience Institute, gave greater insights…